Jci_page_head_homepage_01 Jci_page_head_homepage_02
Jeffrey E. Galvin, Mark E. Hemric, Kent Ward, Madeleine W. Cunningham
Published in Volume 106, Issue 2
J Clin Invest. 2000; 106(2):217–224 doi:10.1172/JCI7132
Abstract | Full text | PDF
Options: View larger image (or click on image)
Medium
Figure 5

(a) Inhibition of mAb 3.B6 binding to GlcNAc-BSA by laminin. Monoclonal antibody 3.B6 (10 μg/mL) was mixed with increasing amounts of inhibitor (0–500 μg/mL), and binding of mAb to GlcNAc-BSA on the microtiter plate was detected by ELISA; mAb 3.B6 binding to BSA coated wells was negative. Inhibitors are as follows: squares, laminin; circles, BSA. Percentage of inhibition was calculated by the formula used in Figure 2. (b) Reactivity of mAb 3.B6 with laminin in the immunodot blot assay. Fifty micrograms laminin was adsorbed onto nitrocellulose and reacted with mAb 3.B6 (10 μg/mL), and mAb 3.B6 binding to laminin was detected by peroxidase-conjugated anti-human IgM antibodies followed by substrate. Monoclonal antibody 3.B6 did not bind to BSA, and the IMDM medium control was not laminin reactive.